Abstract: The invention discloses nanoparticles offering an extended time before capture by the reticulo-endothelial system. Said particles are composed of an ethylene and/or propylene polyoxide polylactic copolymer optionally mixed with a polylactic polymer.

Abstract: There are disclosed a controlling agent and an antifouling composition against harmful aquatic organisms, which include a particular N-phenylisothiazolone derivative of the formula: ##STR1## wherein X.sup.1 and X.sup.2 are the same or different and are independently hydrogen, chlorine or bromine; and R is haloalkoxy. Also disclosed is a method for preventing or inhibiting the adhesion of harmful aquatic organisms to water-exposed articles, which includes applying the antifouling composition to the water-exposed articles.

Abstract: The present invention provides a wound dressing composed of a hydrogel with the principal component being a vinyl alcohol polymer of a viscosity average polymerization degree of 300 or more, wherein the vinyl alcohol polymer contains 5 to 50 mol % of one or more vinyl ester units represented by the following formula (I): ##STR1## and the vinyl alcohol polymer has a block character (.eta.) of 0.6 or less, the block character being represented by the following mathematical formula (II);.eta.=?OH, VES!/2?OH!?VES! (II)Because the wound dressing of the present invention is excellent in terms of transparency, flexibility, hot water resistance, water absorption, and safety, the dressing is useful for the treatment and promotion of the healing of wounds including general wounds such as abrasions, cuts and acne; surgery wounds such as excision wounds and dermabrasions; burns; ulcers; and pressure sores.

Abstract: A transparent gel air freshener and method of preparing the same. The gel composition comprises an aqueous gel, a fragrance, a surfactant and a co-solvent. The gel is transparent and free from visible particles and inhomogeneities, has a uniform texture and a continuous structure, and includes volatile scented components. The gel is capable of suspending solids such as botanicals therein for decorative effect. The method provides for preparation of a such a gel air freshener, including the suspension of botanicals therein, while maintaining the clarity, texture, and structure of the gel. The method includes the steps of preparing a gel composition and cooling the gel composition. Botanicals may be added to the gel composition when it has gelled enough to support the botanicals on the gel surface.

Abstract: Implants, prostheses, and stents comprising a polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer.

Abstract: Disclosed are terminally sterilized osteogenic devices for implantation into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble carrier which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.

Abstract: An emulsifier for emulsifying pesticide concentrates, the emulsifier consisting essentially of: (i) a sulfate as represented by general formula I: ##STR1## wherein R.sub.1 is an alkyl group having 8 or 9 carbon atoms, R.sub.2 is an alkyl radical having from 8 to 22 carbon atoms, x is a number from 4 to 10 and, y is a number from 2 to 20; and (ii) a nonionic surfactant selected from the group consisting of alkoxylated block copolymers of C.sub.8-12 alkylphenols, castor oil ethoxylates, mono- and di-esters of ethylene glycol, ethoxylated C.sub.8-22- alcohols, sorbitan esters, ethoxylated sorbitan esters, ethylene oxide-propylene oxide block copolymers, propoxylated-ethoxylated butanols, and mixtures thereof.

Abstract: The hair growth promoter of the present invention contains extracts from two or three of mulberry bark (mulberry root bark of Morus bombycis Koidzumi and Morus alba Linne or a plant of the same genus as that of them), leaves of persimmon (Diospyros Kaki Thunb) and leaves of paulownia (Paulowinia tomantosa Steud. or plants of the same genus as that thereof) as the active ingredients for restoring or growing hair.The hair growth promoter of the present invention has an effect of accelerating the proliferation of the human hair follicle cells which constitute the human hair follicle and which form the hair and also an effect of accelerating the hair growth in mice. When the hair growth promoter is applied to the human beings, excellent effects of preventing the hair from falling out and accelerating the hair growth are obtained. Thus, the hair growth promoter of the present invention is effectively usable for the treatment or prevention of an alopecia such as premature alopecia or alopecia diffuse.

Abstract: An aqueous suspension of solid lipoid nanoparticles, comprising at least one lipid and preferably also at least one emulsifier, for topical application to the body, is provided. The solid lipoid nanoparticles have a mean particle size of between 50-1000 nm and their concentration is between 0.01-60 wt %, by weight of the suspension. Also topical preparations, comprising said suspension of solid lipoid nanoparticles, are provided. A medicament can be incorporated into the continuous phase of the suspension or in a vehicle, which is added to said suspension.The invention further provides manufacturing methods for the aqueous suspension of solid lipoid nanoparticles as well as for preparations comprising such suspension.

Abstract: Topical anti-hyperalgesic film-forming compositions and methods of using compositions for the treatment of peripheral hyperalgesia comprising:a) a compound of the formula ##STR1## wherein M is ##STR2## wherein: R, R.sup.2, R.sup.3, R.sup.4, R.sup.7, Ar.sup.1 and Ar.sup.2 are as defined in the specification;b) a film-forming polymeric material containing the hyperalgesic compound; andc) an aqueous pharmaceutically acceptable carrier.

Abstract: Methods are provided for the treatment of a host suffering from head ache pain with topical applications of a local anesthetic. The topical local anesthetic composition comprises an effective amount of a local anesthetic in combination with eucalyptol as a penetration enhancing agent, and optionally an additional penetration enhancing agent. The topical local anesthetic composition is applied to a keratinized skin site proximal to target nerves associated with the headache pain, usually to the supraorbital or occipital regions of the head. Upon application of the topical composition, the local anesthetic rapidly penetrates the skin to block conduction in the target nerves and provide pain relief to the host.

Abstract: A novel polymeric platinum complex represented by the following formula (I): ##STR1## wherein, S, A, x, m and n are defined as above, a process for preparation thereof, and the use thereof as an anticancer agent.

Abstract: A cholesterol-lowering drug which comprises, as the main ingredient, a non-crosslinked anion exchange resin consisting of structural units represented by the general formula (I): ##STR1## wherein R.sub.1 represents a benzyl group or an alkyl group having 1 to 20 carbon atoms, R.sub.2 and R.sub.3 may be identical with, or different from, each other and each represent a lower alkyl group having 1 to 4 carbon atoms, R.sub.4 represents a hydrogen atom or a lower alkyl group, X represents a physiologically acceptable counter ion, n is an integer of from 1 to 3, and p is an average degree of polymerization ranging from 10 to 10,000.

Abstract: This invention relates to a fast drying iodine complex solution having film forming capability and skin substantivity which solution consists essentially of:(a) between 1 and 25 wt % polyvinyl pyrrolidone/iodine (PVP/I) complex;(b) between 5 and 15 wt % vinyl pyrrolidone/vinyl acetate copolymer (PVP/VA);(c) between 0.5 and 1.5 wt % non-plasticizing polyethylene glycol (PEG);(d) between 35 and 75 wt % C.sub.1 to C.sub.4 alkanol;(e) between 12 and 35 wt % deionized water and(f) between 0 and 2.5 wt % of 1-vinyl-3-(E)-ethylidene pyrrolidone, based on total composition.The invention also relates to the method of preparing the film forming solution which has a drying time of less than 5 minutes.

Abstract: A feed supplement for ruminants comprising a gluconeogenic compound, which can be digested in the rumen and a hydrogenated fatty acid, which is rumen inert, is described. One example of such a feed supplement comprises 30% gluconeogenic compounds, by weight and 30% C.sub.14 -C.sub.22 hydrogenated fatty acids by weight, the balance being essentially inert compounds. The feed supplement of the present invention can be used in the treatment of or for the prevention of negative energy or a nutrient imbalance. A method of treating or preventing a nutrient imbalance by administering to a ruminant in need thereof, a daily dosage amount of a composition comprising a gluconeogenic compound, which can be digested in the rumen and a hydrogenated fatty acid, which is rumen inert, for from 10-21 days prior to calving to 21-42 days after calving.

Abstract: The present invention concerns a method for treating fibrotic conditions by administration of an effective amount of an antifibrotic agent. The antifibrotic agent is preferably a proline analog, such as cis-4-hydroxy-L-proline (cHyp). The antifibrotic agent is operatively linked to a monomer or a polymer, with or without a linking compound, e.g., lysine. Intravenous administration is preferred. The present method facilitates the delivery and release of the antifibrotic agent to inhibit collagen accumulation and thereby to treat fibrosis where collegen metabolism is implicated. A reduced quantity of the antifibrotic agent and a corresponding reduction in the potential for toxicity resulting from prolonged administration thereof may be realized.

Abstract: The invention relates to compounds of formula: ##STR1## in which: w is 0, 1 or 2;x is between 2 and 10;y is between 0 and 5;R denotes a methyl, ethyl, hydroxyethyl or benzyl radical;X.sup..crclbar. denotes an inorganic or organic anion; andn is an integer or decimal number between 1 and 15;the [C.sub.5 H.sub.6 N.sub.2 R.sup.+ ] group representing the following structures, taken as a mixture or individually: ##STR2## as well as their use as a biocidal agent or preservative.

Abstract: A cyanoacrylate adhesive is applied onto surface skin areas prone to ulceration or irritation so as to inhibit irritation of the surface skin due to contact with an artificial device such as prosthetic devices, bandages, casts, etc.

Abstract: The present invention relates to administration forms having an extended gastric residence time, in the preparation of which mixtures of polymers containing lactam groups and polymers containing carboxyl groups are used, and which are distinguished both by marked swelling properties and by high dimensional stability in the swollen state.

Abstract: Methods of amelioration, treatment and prevention for restenosis and related disorders are provided. Methods involve the administration of nitric oxide by a nitric oxide delivery means comprising a restenosis-ameliorating or therapeutically/prophylactically effective amount of either a polymer to which is bound a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group a compound comprising a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group. Also provided are nitric oxide delivery means comprising such nitric oxide-releasing polymers or compounds for use in such methods. Preferably, the delivery means is coated with a nitric oxide-releasing polymer, which may be biodegradable, and enables the controllable and predictable release of NO to a given site in such a manner that effective ameliorating, prophylactic or therapeutic dosing is realized.